Hims & Hers Pivots to Branded Drugs in High-Stakes Strategy Shift
Published on 03/22/2026 at 04:55 | Redaktion boerse-global.de
The telehealth company Hims & Hers has executed a dramatic strategic reversal, transforming from a legal adversary into a distribution partner for pharmaceutical giant Novo Nordisk. The settlement of a months-long dispute will see Hims & Hers begin selling Novo's branded weight-loss drugs, Ozempic and Wegovy, through its platform by late March, with prices starting at $149 per month. While this pivot opens a significant new revenue channel, it introduces substantial execution risks and near-term financial pressures.
A Turbulent Path to Partnership
This new alliance follows a period of significant conflict. Earlier this year, shortly after the launch of a Wegovy pill on January 5, Hims & Hers attempted to market its own compounded version of the medication. This move prompted a patent infringement lawsuit from Novo Nordisk, a reprimand from the U.S. FDA, and a threat of investigation from the Department of Justice. The telehealth firm subsequently retreated from its position.
The resolution is a formal cooperation agreement. In exchange for Novo withdrawing its lawsuit, Hims & Hers gains access to the full branded product portfolio. This includes Ozempic injections in three dosages, alongside Wegovy injections and pills across a total of six strengths. The company has already opened a waiting list for these products.
Fundamental Business Model Overhaul
The strategic shift is clear and substantial. Hims & Hers is largely discontinuing the advertising and sale of its compounded GLP-1 medications. Its future focus will be on approved, branded pharmaceuticals. Access to compounded alternatives will be maintained only for a "limited group" of patients whose needs cannot be met by the branded assortment.
Management's long-term vision is ambitious: to establish the company as the "world's largest consumer health platform for affordable, approved medications." By 2030, the leadership team is targeting revenue of $6.5 billion and adjusted EBITDA of $1.3 billion.
Near-Term Financial Headwinds Emerge
The transition is already impacting financial guidance. For the fourth quarter of 2025, Hims & Hers reported revenue of $617.8 million, a 28% year-over-year increase. However, its forecast for Q1 2026—$600 to $625 million—fell short of the analyst consensus estimate of $653 million. The company attributes this primarily to a one-time, $65 million impact from changed shipping procedures within its weight management segment, which it characterizes as temporary.
Should investors sell immediately? Or is it worth buying Hims & Hers?
For the full 2026 fiscal year, the company anticipates revenue in the range of $2.7 to $2.9 billion.
Analysts Offer Cautious Endorsement
Equity researchers have responded with a mixed, though generally constructive, outlook. Barclays analyst Glen Santangelo raised his price target from $25 to $29, reaffirming an Overweight rating. Leerink Partners increased its target from $17.50 to $25 but maintained a neutral Market Perform rating, citing the weaker-than-expected Q1 guidance.
The consensus among 17 analysts, as of March 16, 2026, is a Hold recommendation, with an average twelve-month price target of $31.29.
The central question remains whether the new branded drug revenue can fully offset the loss of income from compounded medications. Success hinges critically on the speed at which Hims & Hers can migrate its 2.5 million subscribers to the new products and the actual pace of demand growth for Wegovy and Ozempic on its platform.
Ad
Hims & Hers Stock: New Analysis - 22 March
Fresh Hims & Hers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
